Erlotinib
CRCST-L-0005
Phase 2 small_molecule terminated
Quick answer
Erlotinib for Leptomeningeal Carcinomatosis is a Phase 2 program (small_molecule) at Solid Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Solid Biosciences
- Indication
- Leptomeningeal Carcinomatosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated